By VETTAPHARMA reporter – Derek Roche: Eli Lilly and Company will present new oncology data across multiple tumor types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting late-stage pipeline progress and expansion of targeted cancer therapies.
The presentations include updates from several clinical programmes across breast cancer, gastrointestinal cancers, lung cancer, and hematologic malignancies, reinforcing Lilly’s strategy of building a diversified oncology portfolio supported by precision medicine and biomarker-driven approaches.
For Jaypirca (pirtobrutinib), presentations include findings from the BRUIN Phase I/II trial, evaluating the non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, with focus on durable response and long-term disease control.
For imlunestrant, Lilly will present data from the EMBER-3 Phase III trial, evaluating the oral selective estrogen receptor degrader (SERD) in estrogen receptor-positive, HER2-negative advanced breast cancer, with analyses focused on progression-free survival and endocrine resistance management.
Additional presentations involve olomorasib, Lilly’s KRAS G12C inhibitor, including combination studies evaluating targeted approaches in KRAS-mutated solid tumors, particularly non-small cell lung cancer.
The ASCO presentations also include data from immuno-oncology and antibody-drug conjugate programmes, reflecting Lilly’s continued expansion across targeted oncology platforms and combination treatment strategies.
The breadth of presentations aligns with Lilly’s oncology strategy of advancing precision therapies, oral targeted treatments, and biomarker-selected approaches, while expanding across both solid tumors and hematologic cancers.
For patients, the latest clinical findings may support broader treatment options and improved disease management in difficult-to-treat cancers, particularly in settings involving resistance to existing therapies or limited targeted treatment availability.
From a commercial perspective, continued advancement of late-stage oncology programmes and additional clinical evidence across multiple tumor types may support future regulatory filings, portfolio expansion, and long-term growth in Lilly’s oncology business.
